BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Hybridon, Inc. 

345 Vassar Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: n/a Fax:


SEARCH JOBS




Industry
Biotechnology

Segment
Drug Discovery





 Company News
Hybridon, Inc. (HBY) Reports 2004 Financial Results10/19/2005 5:13:07 PM
Hybridon, Inc. (HBY) Presents New Preclinical Antitumor Data At American Association for Cancer Research Supporting Its IMOxine Development Program10/19/2005 5:13:05 PM
Hybridon, Inc.'s (HBY) Toll-Like Receptor 9 Agonist Enhances Antitumor Activity Of Cetuximab In Preclinical Studies10/19/2005 5:12:55 PM
Hybridon, Inc. (HYBN) To Present At Biotechnology Industry Organization (BIO) CEO And Investor Conference10/19/2005 5:12:48 PM
BioSpace Celebrates A Decade Of Genetown™10/19/2005 5:12:28 PM
Hybridon, Inc. (HYBN) Provides Updated Interim Results For The Phase 1 Trial Of IMOxine(TM)10/19/2005 5:12:16 PM
Hybridon, Inc. (HYBN) Announces Two Presentations At The American College Of Allergy, Asthma, & Immunology Annual Meeting10/19/2005 5:12:13 PM
Hybridon, Inc. (HBY) To Present At Two Upcoming Conferences10/19/2005 5:12:02 PM
Hybridon (HYBN) Initiates Phase 2 Trial Of Its Oncology Drug Candidate, IMOxine(TM) 10/19/2005 5:11:56 PM
Hybridon (HYBN) To Present At Rodman & Renshaw Techvest 6th Annual Healthcare Conference 10/19/2005 5:11:55 PM
12345